Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial. In November, Pfizer acquired Metsera for up to $10 billion following a fierce bidding war with Novo Nordisk. The mid-stage trial was studying the monthly maintenance dosing of the drug, PF’3944, to